Baseline amyloid-PET centiloids and tau-PET SUVRs as well as longitudinal tau-PET change rates stratified by Aβ and diagnostic status are shown in Fig. 1, illustrating AD-typical temporo-parietal tau-PET uptake with increased clinical disease severity in the Aβ-positive (Aβ+) groups, while no tau-PET increase was found in Aβ-negative (Aβ-) groups. This evidence concerns the gene MAPT and Alzheimer disease.